Victoria Taylor, British Heart Foundation at "Journeys of Health-Tech Innovation" Nov 30th 2015
•Descargar como PPTX, PDF•
1 recomendación•1,124 vistas
Victoria Taylor, British Heart Foundation, "Bridging the gap between discovery and commercialisation: A charity's perspective" - slides from Journeys of Health-Tech Innovation: Products to Market
Recomendados
Recomendados
Más contenido relacionado
La actualidad más candente
La actualidad más candente (10)
Destacado
Destacado (8)
Similar a Victoria Taylor, British Heart Foundation at "Journeys of Health-Tech Innovation" Nov 30th 2015
Similar a Victoria Taylor, British Heart Foundation at "Journeys of Health-Tech Innovation" Nov 30th 2015 (20)
Más de Health-Tech Innovation LABS
Más de Health-Tech Innovation LABS (16)
Último
Último (20)
Victoria Taylor, British Heart Foundation at "Journeys of Health-Tech Innovation" Nov 30th 2015
- 1. BRIDGING THE GAP BETWEEN DISCOVERY AND COMMERCIALISATION: a charity’s perspective Victoria Taylor – Research Translation Advisor
- 2. ♥ Research spend of approx. £100m a year ♥ Traditionally hypothesis- driven basic research ♥ Now have a Translational Award to support development of innovative medicines and treatments Who are we?
- 3. Why is BHF supporting translational research? Discovery research Pre-clinical development Clinical development Approval and market IndustryAcademia IndustryFunding gapAcademia Traditionally: Now: ♥ Significant clinical unmet needs remain ♥ BHF now playing a key role to support early stage CV innovation BHF Translational Award
- 4. The BHF now has: ♥ A new Translational Award ♥ A Translational Advisory Group
- 5. How did we get there? ♥ We did our own due diligence ♥ Sought advice from experts ♥ Found our niche
- 6. Aim: to de-risk projects so they attract further investment: Basic research Pre-clinical development Clinical dev. ♥ We want to ensure projects we fund continue along the development pathway (e.g. further charitable funding, industry investment)
- 7. Experts help us select and shape projects: Translational Award Advisory Group Scientific and clinical experts ♥ Key to our process: Flexibility, support, mentorship
- 8. Application tips: ♥ Target validation and clinical relevance ♥ Think beyond project you want funding for – what does your proof of concept clinical trial look like? Have you spoken to the regulatory agencies? ♥ Would it make sense to outsource some of the work? ♥ Competitive advantage (proof of relevance)
- 9. Project examples: ♥ Changing clinical end-points ♥ Fund regulatory consultant and FDA meeting to understand if development plan is sensible ♥ Lead optimisation of a small molecule ♥ Outsource work and hire a project manager Often the science is not the hurdle… ♥ 20 outlines 9 invited to full application so far made 4 awards
- 10. Next steps.. more than just a funding scheme: ♥ Engaging with industry and involving them early on in the process ♥ Education workshops for academics ♥ Mind-set change
- 11. BHF Academia Industry VC Clinicians Patients Charities BHF can be a cardiovascular hub for:
Notas del editor
- Fund over 100m a year Largest CV
- Kickstart academic research – we have direct links with academia Small award value Pre-clinical development of novel technologies that address an unmet clinical need Up to £250,000; milestone driven
- The key differentiator for this award scheme is our commitment to support and mentor academics through the award process and beyond. We recognise the mind-set change required from basic science grants, so work closely and informally with academics, drawing on our Advisory Group’s experience and contacts to ensure that each project is designed with the right goals to ensure the best chance of success. Backgrounds: VC, biotech, pharma, consultancy, CROs, patent attorneys Expertise: pre-clinical development of small and large molecules, repurposing, devices, diagnostics, biomarkers, biologics; IP Internal BHF Medical Directors >650 principal investigators 30 KOLs (BHF Professors) 3 BHF Committees (Projects, Fellowships, Chairs & Programmes) Strong relationships with international academics and clinicians
- The BHF has a unique specialist expertise in CVS science. It also has: Substantial contacts in pharma, biotech, imaging, devices and diagnostic companies that can be shared Regular updates of industry needs and changing priorities Growing contacts with institutional/ VC investors to help with exit strategies at pre-clinical Affiliations with other charities to help more continuous funding schemes